KCM
EGRX

Kennedy Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Kennedy Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-55,748
Closed -$292K – 766
2024
Q1 		$292K Sell
55,748
-18,061
-24% -$99.1K 0.01% 678
2023
Q4 		$386K Buy
73,809
+37,323
+102% +$368K 0.01% 644
2023
Q3 		$575K Buy
+36,486
New +$655K 0.01% 606
2021
Q4 		– Sell
-96,191
Closed -$5.37M – 651
2021
Q3 		$5.37M Sell
96,191
-4,513
-4% -$222K 0.12% 322
2021
Q2 		$4.31M Sell
100,704
-12,476
-11% -$515K 0.09% 383
2021
Q1 		$4.72M Buy
+113,180
New +$5.26M 0.1% 383

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kennedy Capital Management's EGRX Position: Q2 2024 in Review

Kennedy Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 55,748 shares — an estimated $292K sold.

Kennedy Capital Management first reported a position in EGRX in Q1 2021 and held it in 6 quarters. The position peaked at $5.37M in Q3 2021. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Kennedy Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 55,748 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $292K.
  • Kennedy Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2021 and held it in 6 quarters.
  • Kennedy Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $5.37M in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Kennedy Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.